A REAL-WORLD COMPARISON OF HYPERTENSION AND CARDIOVASCULAR ADVERSE EVENTS WITH ACALABRUTINIB VS IBRUTINIB IN PATIENTS WITH TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA